Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab study in relapsed or refractory multiple myeloma
PACTR202606758025670Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of belantamab, belantamab mafodotin, pomalidomide and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by GSK. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
belantamabbelantamab mafodotinpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on PACTR202606758025670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606758025670.